The H. L. accompanied by BEACOPP program is a questionable disease in the field of blood tumors, with clinical performance being complex and often involving multi-system congestion.
Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in matching the needs of a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the HL accompanying BEACOPP program.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.